---
title: "Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294412092.md"
description: "Eli Lilly & Co. (LLY) shares fell 4.55% to $1,154.97 on Thursday, underperforming the broader market and key competitors like Johnson & Johnson, Pfizer, and AbbVie despite a positive trading session for major indices. This marks the stock's second consecutive day of losses, with LLY closing 7.56% below its 52-week high. Trading volume matched its 50-day average."
datetime: "2026-07-30T20:31:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294412092.md)
  - [en](https://longbridge.com/en/news/294412092.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294412092.md)
generator: "portal-rs"
---

# Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Eli Lilly & Co. (LLY) slipped 4.55% to $1,154.97 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.66% to 7,437.63 and the Dow Jones Industrial Average rising 1.19% to 52,208.06.

This was the stock's second consecutive day of losses.

Eli Lilly & Co. closed 7.56% below its 52-week high of $1,249.45, which the company reached on July 7th.

The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) fell 3.66% to $255.82, Pfizer Inc. (PFE) fell 0.95% to $24.91, and AbbVie Inc. (ABBV) fell 2.24% to $257.41.

Trading volume (3.0 M) eclipsed its 50-day average volume of 3.0 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 30, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-30-26 1631ET

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Eli Lilly and Company $LLY Shares Purchased by Canada Pension Plan Investment Board](https://longbridge.com/en/news/297479625.md)
- [Evolve Private Wealth LLC Lowers Stock Holdings in Eli Lilly and Company $LLY](https://longbridge.com/en/news/297282696.md)
- [Eli Lilly and Company $LLY Shares Sold by Addison Advisors LLC](https://longbridge.com/en/news/296871178.md)
- [Lilly's $9.94 Billion Mounjaro Franchise Wins a Heart-Risk Label](https://longbridge.com/en/news/297356212.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**